Products
Online Inquiry
GNF4877
Cat. No.:
OB0225WX-1733
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
GNF4877 is a powerful dual inhibitor of DYRK1A (IC50: 6 nM) and GSK3β (IC50: 16 nM) that effectively blocks the nuclear export of the transcription factor NFATc.
Synonym:
2041073-22-5; (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid; GNF-4877; (3R)-1-[3-[[3-amino-6-(2-fluoro-5-propan-2-yloxyphenyl)pyrazine-2-carbonyl]amino]pyridin-4-yl]piperidine-3-carboxylic acid; (3R)-1-{3-[3-amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-amido]pyridin-4-yl}piperidine-3-carboxylic acid
CAS No.:
2041073-22-5
Compound CID:
139600315
Formula:
C25H27FN6O4
Formula Weight:
494.52
Specification
Targets&IC50:
DYRK1A: 6 nM; GSK-3β: 16 nM
Relative Density:
1.367 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GNF4877 is utilized in metabolic research as an activator of pancreatic beta-cell proliferation to investigate potential mechanisms for increasing beta-cell mass and improving insulin production.
Library Information
Target:
DYRK; GSK-3
Receptor:
DYRK1A; GSK-3β
Pathways:
Stem cells; Cell cycle/Checkpoint; Tyrosine kinase/adaptors; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-23
Plate Location:
b8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2mM DMSO
DMSO Max Solubility:
4.17 mg/mL; 8.43 mM
